The latest price target for Zentalis Pharma (NASDAQ:ZNTL) was reported by Oppenheimer on September 16, 2024. The analyst firm set a price target for $20.00 expecting ZNTL to rise to within 12 months (a possible 380.77% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Zentalis Pharma (NASDAQ:ZNTL) was provided by Oppenheimer, and Zentalis Pharma reiterated their outperform rating.

The last upgrade for Zentalis Pharmaceuticals Inc happened on August 12, 2024 when Wedbush raised their price target to $4. Wedbush previously had an underperform for Zentalis Pharmaceuticals Inc.

The last downgrade for Zentalis Pharmaceuticals Inc happened on June 20, 2024 when UBS changed their price target from $28 to $5 for Zentalis Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zentalis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zentalis Pharma was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Zentalis Pharma (ZNTL) rating was a reiterated with a price target of $20.00 to $20.00. The current price Zentalis Pharma (ZNTL) is trading at is $4.16, which is out of the analyst’s predicted range.